Bradykinin B1 receptor antagonists as novel analgesics: a retrospective of selected medicinal chemistry developments.
Bradykinin B(1) receptor antagonists embody a potentially novel approach for the treatment of chronic pain and inflammation. The identification of non-peptide B(1) antagonists has been a notable advance in the kinin field that will allow evaluation of their therapeutic potential in the clinical realm. The current review is a high level summary of our contributions to the area that culminated in the discovery of a clinical candidate.
Kuduk
Scott D
SD
Department of Medicinal Chemistry, Merck Research Laboratories, West Point, Pennsylvania 19486, USA. scott_d_kuduk@merck.com
Bock
Mark G
MG
D000700:Analgesics / Q000737:chemistry* / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D065169:Bradykinin B1 Receptor Antagonists; D002626:Chemistry, Pharmaceutical; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D010146:Pain / Q000188:drug therapy; D043783:Receptor, Bradykinin B1 / Q000378:metabolism; D013329:Structure-Activity Relationship
D000700:Analgesics; D065169:Bradykinin B1 Receptor Antagonists; D043783:Receptor, Bradykinin B1